In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Heart Failure, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668e
Vancouver
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668e
BibTeX
@article{euvimed2023,
title = {In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668e}
}
EUVIMED